# Ray Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ray-therapeutics

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.raytherapeutics.com
- Total disclosed funding: $145M
- Latest round: Series B (Apr 21, 2026)
- Investors on record: 11

## About

Founded in 2021 and based in CA, US, Ray Therapeutics, Inc is a biotech company developing optogenetic gene therapies for patients with blinding diseases. The company was co-founded by Paul Bresge, who also serves as the Chief Executive Officer of the company, Sean Ainsworth and Dr. Zhuo-Hua Pan.In April 2026, Ray Therapeutics, Inc. raised USD 125 million in series B funding led by Janus Henderson Investors, with participation from Adage Capital Management, Franklin Templeton, Invus Financial Advisors, Marshall Wace, 4BIO Capital Partners, Deerfield Management, MRL Ventures Fund, Norwest Venture Partners, Novo Holdings, and Platanus Ventures.

The company's lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical needs. Ray-001 is intended to be a one-time treatment via intravitreal injection that is sustainable for a lifetime. The firm pursues multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company will use the April 2026 funding to support late-stage clinical development and commercial readiness for its lead program RTx-015 in retinitis pigmentosa and to advance clinical studies for RTx-021 in Stargardt disease and geographic atrophy.

## Funding rounds

- Series B, Apr 21, 2026, $125M — Norwest Venture Partners, Novo Holdings, Marshall Wace, Adage Capital Management, Janus Henderson Investors, Invus Financial Advisors, Deerfield Management, Franklin Templeton, 4BIO Capital Partners, MRL Ventures Fund, Platanus Ventures
- Series A, May 15, 2023, $14M — Norwest Venture Partners, Novo Holdings, Deerfield Management, 4BIO Capital Partners, MRL Ventures Fund, Platanus Ventures
- Seed, May 25, 2021, $6M — 4BIO Capital Partners

## Investors

- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Seed, Series A, Series B
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A, Series B
- Novo Holdings — Series A, Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A, Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A, Series B
- Platanus Ventures (https://capitalatlas.ai/funds/platanus-ventures) — Series A, Series B
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- Adage Capital Management — Series B
- Janus Henderson Investors — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B